ArticleMedical science monitor : international medical journal of experimental and clinical research2014
Effect of high dose vitamin C on Epstein-Barr viral infection.
Article in Medical science monitor : international medical journal of experimental and clinical research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 55 citations in OpenAlex.
- Vitamin C and COVID-19 treatment: A systematic review and meta-analysis of randomized controlled trials.Diabetes & metabolic syndromePooled it
- Safety and effectiveness of high-dose vitamin C in patients with COVID-19: a randomized open-label clinical trial.European journal of medical research · 2021Trial
- Underuse of Pharmacologic Therapies for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Before Specialist Evaluation.Annals of family medicine · 2026Article
- Web of Science-Based Visualization of Mapping Global Scientific Production on Epstein-Barr Virus-Associated Autoimmune Diseases: A Bibliometric Study.Health science reports · 2025Article
- Patient-reported treatment outcomes in ME/CFS and long COVID.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Exploring the mechanism of vitamin C on the co-expressed genes of papillary thyroid carcinoma and Epstein-Barr virus based on bioinformatics, network pharmacology and molecular docking analysis.Discover oncology · 2025Article
- Calcitriol reduces Newcastle disease virus replication by modulating galectin 3 and pro-inflammatory cytokines.Archives of virology · 2024Article
- Association between composite dietary antioxidant index and Epstein-Barr virus infection in children aged 6-19 years in the United States: from the national health and nutrition examination survey 2007-2010.Frontiers in nutrition · 2024Article
- Treatment of Epstein-Barr Induced Hepatitis with High Dose Intravenous Vitamin C: A Case Report.Integrative medicine (Encinitas, Calif.) · 2023Article
- The Dietary Flavonol Kaempferol Inhibits Epstein-Barr Virus Reactivation in Nasopharyngeal Carcinoma Cells.Molecules (Basel, Switzerland) · 2022Article
- The protective role of vitamin C in the management of COVID-19: A Review.The Journal of the Egyptian Public Health Association · 2021Review
- The Effects of Vitamin C on the Multiple Pathophysiological Stages of COVID-19.Life (Basel, Switzerland) · 2021Review
- Covid 19: Diet Composition and Health.Nutrients · 2021Review
- Low level of Vitamin C and dysregulation of Vitamin C transporter might be involved in the severity of COVID-19 Infection.Aging and disease · 2021Article
- Targeting the signaling in Epstein-Barr virus-associated diseases: mechanism, regulation, and clinical study.Signal transduction and targeted therapy · 2021Review
- Vitamins, supplements and COVID-19: a review of currently available evidence.Drugs in context · 2021Review
- Food policy, nutrition and nutraceuticals in the prevention and management of COVID-19: Advice for healthcare professionals.Trends in food science & technology · 2020Review
- Cytokine storm in aged people with CoV-2: possible role of vitamins as therapy or preventive strategy.Aging clinical and experimental research · 2020Review
- Quercetin and Vitamin C: An Experimental, Synergistic Therapy for the Prevention and Treatment of SARS-CoV-2 Related Disease (COVID-19).Frontiers in immunology · 2020Review
- Editorial: Vitamin C in Cancer and Infectious Diseases: Physiological, Biochemical and Therapeutic Interventions.Frontiers in physiology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Many natural compounds were tested for the ability to suppress viral replication. The present manuscript details an analysis of high dose vitamin C therapy on patients with EBV infection. Material and Methods The data were obtained from the patient history database at the Riordan Clinic. Among people in our database who were treated with intravenous vitamin C (7.5 g to 50 g infusions) between 1997 and 2006, 178 patients showed elevated levels of EBV EA IgG (range 25 to 211 AU) and 40 showed elevated levels of EBV VCA IgM (range 25 to 140 AU). Most of these patients had a diagnosis of chronic fatigue syndrome, with the rest being diagnosed as having mononucleosis, fatigue, or EBV infection. Results Our data provide evidence that high dose intravenous vitamin C therapy has a positive effect on disease duration and reduction of viral antibody levels. Plasma levels of ascorbic acid and vitamin D were correlated with levels of antibodies to EBV. We found an inverse correlation between EBV VCA IgM and vitamin C in plasma in patients with mononucleosis and CFS meaning that patients with high levels of vitamin C tended to have lower levels of antigens in the acute state of disease. In addition, a relation was found between vitamin D levels and EBV EA IgG with lower levels of EBV early antigen IgG for higher levels of vitamin D. Conclusions The clinical study of ascorbic acid and EBV infection showed the reduction in EBV EA IgG and EBV VCA IgM antibody levels over time during IVC therapy that is consistent with observations from the literature that millimolar levels of ascorbate hinder viral infection and replication in vitro.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.